ECSA Day 2026

→ Europe/Paris
RC 150 - Auditorium (IARC)

RC 150 - Auditorium

IARC

25 avenue Tony Garnier, Lyon, France
Description

ECSA Scientific Day 2026

24–25 November 2026 · IARC Auditorium (in person)

Showcasing the work of early career and visiting scientists — scientific exchange, professional development, and networking.

Registration is open until November 9.

Call for Abstracts

Abstract submission is now closed. 

Abstracts are submitted across three tracks:

  • Epidemiology and Prevention Strategies
  • Novel Interventions and Public Health Impact
  • Molecular and Biomarker-Based Prevention

All accepted abstracts are presented as oral presentations. The top three abstracts in each track receive an Abstract Award and an extended presentation slot. Oral Presentation Awards also recognize the top presentations in each track.

  • Tuesday 24 November
    • Welcome to ECSA Day RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
    • Cancer Prevention Europe: Early Career Network RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
      • 1
        ECSA meets CPE ECN: discover Cancer Prevention Europe's Early Career Network
        Speaker: Josefina Orliacq (ENV)
    • Cancer Etiology, Epidemiology & Risk Factors: Part 1 RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
      • 2
        Beyond the Ink: Global Evidence Linking Tattooing to Hepatitis B and C Infection

        Background/Aim: As tattooing becomes increasingly popular worldwide, its potential contribution to blood-borne viral infections remains a public health concern. Hepatitis B (HBV) and C (HCV) infections are major causes of liver cancer. We aimed to quantify the associations between tattooing and HBV/HCV infection globally and examine their consistency across populations and geographical settings.

        Methods: We systematically searched PubMed, Embase, and Web of Science through October 2025. Observational studies reporting laboratory-confirmed HBV/HCV infection were included. Adjusted odds ratios (ORs) were pooled using random-effects meta-analysis, with subgroup and sensitivity analyses assessing geographical variation and potential confounding.

        Results: We included 238 publications representing 240 independent study samples and 591,527 participants across all six WHO regions. Tattooing was associated with more than twice the odds of HBV infection (adjusted OR 2.30, 95% CI 1.85–2.86) and three times the odds of HCV infection (3.03, 2.70–3.40). Associations persisted in analyses accounting for injecting drug use and sexual risk behaviours. Significant geographical variation was observed, highlighting the importance of epidemiological context.

        Conclusion: This comprehensive global synthesis identifies tattooing as an important correlate of HBV/HCV infection, with implications for liver cancer prevention. Findings support strengthened infection prevention during tattooing and further evaluation of tattoo history and circumstances in risk-based hepatitis testing strategies.

        Speaker: Loucine Sazian (IARC)
      • 3
        From Adiposity to Organ Dysfunction: Physical Activity, Diet, and the Risk of Clinical Obesity in the UK Biobank

        Background: Physical activity (PA) and diet are key modifiable lifestyle factors influencing obesity. Understanding the transition from preclinical to clinical obesity is important because clinical obesity is associated with substantially greater health risks. However, the role of lifestyle factors in this transition remains poorly understood. We assessed the independent and joint associations of PA and diet quality with the risk of progression from preclinical to clinical obesity.
        Methods: We analyzed 159,959 UK Biobank participants with preclinical obesity. Individuals with baseline cancer, cardiovascular disease, organ dysfunction, or without excess body fat were excluded. PA and diet were assessed at baseline using self-reported questionnaires. PA was quantified as metabolic equivalent (MET)-hours/week, and diet quality was summarized using a score based on major food groups. Incident clinical obesity was defined as the first ICD-coded event attributable to excess body fat, according to the Lancet Diabetes & Endocrinology Commission framework. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for independent and joint associations. Preventive fractions for the population (PFPs) were calculated using adjusted HRs and exposure prevalence among cases.
        Results: During a median follow-up of 14 years, 66,697 participants progressed to clinical obesity, corresponding to an incidence rate of 33.2 per 1,000 person-years. Higher PA (HR 0.92, 95% CI 0.90-0.94) and better diet quality (HR 0.94, 95% CI 0.93-0.96) were each associated with lower risk. Participants with both higher PA and better diet quality had the lowest risk (HR 0.87, 95% CI 0.84-0.90). The corresponding PFPs were 4.8%, 1.9%, and 6.0%, respectively.
        Conclusions: Higher PA and better diet quality, particularly in combination, were associated with a reduced risk of progression from preclinical to clinical obesity, supporting integrated lifestyle interventions for obesity prevention.

        Speaker: Dr Alem Abraha (IARC)
      • 4
        Longitudinal BMI Patterns to identify Sensitive Periods for Cancer Etiology and Mortality

        Background: Repeated measurements are increasingly available in epidemiological cohorts, creating opportunities to investigate whether exposures at different ages contribute differently to later health outcomes. However, exposure histories are often reduced to a single summary measure, limiting the ability to identify sensitive periods across the life course.

        Methods: We extended a landmark-based weighted cumulative index of exposure (WCIE) framework to accommodate time-to-event outcomes. The proposed approach combines trajectory reconstruction, multiple imputation, WCIE modelling, and Cox regression to estimate age-specific associations from sparse longitudinal exposure histories. The framework was applied to body mass index (BMI) histories (BMI assessments at three timepoints throughout adulthood) from the EPIC cohort in relation to postmenopausal breast cancer and all-cause mortality after age 55 years.

        Results: BMI associations varied substantially according to age at exposure. For postmenopausal breast cancer, BMI was inversely associated with risk during early adulthood (up to about age 40 years) and positively associated with risk later in life. For all-cause mortality, the strongest positive associations were observed during mid-adulthood (between 30 and 45 years old). The analyses also highlighted that the flexibility of age-specific association functions depends on the amount of longitudinal information available for trajectory reconstruction.

        Conclusion: Making full use of repeated measurements can provide insights into how the association between exposure and disease risk varies across the life c course, which are not accessible with single-exposure measurements or simple exposure summaries. The proposed framework offers a practical approach for identifying sensitive periods from sparse longitudinal data and survival outcomes.

        Speaker: Leonie Courcoul (IARC)
      • 5
        Could Moving More and Sleeping Better Prevent Liver Cancer? Integrating Prospective Cohort Analyses, Mendelian Randomisation and Microsimulation to Quantify the Impact of Physical Activity and Sleep Interventions

        Background/Aim
        Hepatocellular carcinoma (HCC) is an increasingly common and highly lethal cancer that often develops through the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), steatohepatitis (MASH), and cirrhosis. Physical activity and sleep influence key metabolic and inflammatory pathways along this disease continuum, yet the potential public health impact of improving these behaviours remains unclear. We aim to quantify the associations between physical activity and sleep with liver disease progression and HCC risk, evaluate the causal nature of these relationships, and estimate the potential prevention benefits achievable through realistic behavioural interventions.

        Methods
        We will analyse data from the UK Biobank (~500,000 participants) and the European Prospective Investigation into Cancer and Nutrition (EPIC; ~520,000 participants). Associations of physical activity and sleep with MASLD, MASH, cirrhosis and HCC will be assessed using multivariable regression models. Causality will be investigated using two-sample and Bayesian graphical Mendelian randomisation analyses. Together with collaborator Duco Mülder from Erasmus University Medical Center, effect estimates will be incorporated into a newly developed MISCAN-Liver microsimulation model to project the impact of population-wide and risk-targeted interventions on liver disease and HCC outcomes. Key outputs will include HCC cases prevented, life-years gained and cost per life-years gained.

        Results
        No results yet, since the study starts next spring.

        Conclusion
        This will be the first study to combine lifestyle behaviours, prospective cohort analyses, causal inference and microsimulation to quantify behavioural prevention of HCC. It will introduce the first MISCAN Liver model and the first precision targeted projections for behavioural HCC prevention.

        Speaker: Felix Boekstegers (IARC)
    • 10:30
      Coffee break RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
    • Cancer Etiology, Epidemiology & Risk Factors: Part 2 RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
      • 6
        Premature mortality and associated productivity losses due to Epstein-Barr virus: a global analysis

        Background: Emerging aetiological evidence has broadened the spectrum of diseases attributable to Epstein–Barr virus (EBV). Quantifying productivity losses from EBV-associated premature mortality can inform investment in research and prevention.
        Methods: We estimated productivity losses from premature mortality attributable to EBV across seven diseases in 185 countries and territories in 2024: Burkitt lymphoma, diffuse large B-cell lymphoma, extranodal NK/T-cell lymphoma of nasal type, Hodgkin lymphoma, nasopharyngeal carcinoma (NPC), gastric cancer, and multiple sclerosis (MS). Years of productive life lost (YPLL) were calculated using GLOBOCAN 2024, Cancer Incidence in Five Continents, Global Burden of Disease Study 2023, and WHO life tables, defining premature deaths as those occurring before age 65. EBV population attributable fractions were primarily obtained from published studies. Paid and unpaid productivity losses were valued using human capital and opportunity cost approaches, respectively, with economic, labour, and unpaid activity data from international databases.
        Results: In 2024, an estimated 68,854 premature deaths were attributable to EBV, resulting in approximately 0.9 million YPLL. Total productivity losses amounted to US$13.8 billion, equivalent to 0.013% of global GDP. MS (US$4.8 billion) and NPC (US$4.3 billion) were the largest contributors. MS predominated in Europe, North America, and Australia/New Zealand, whereas NPC contributed substantially in Eastern and South-Eastern Asia. Losses were approximately twice as high in males as in females.
        Conclusions: EBV-associated premature mortality imposes substantial societal costs through lost paid and unpaid productivity. These findings support greater investment in EBV research, prevention, and control, with priorities informed by regional differences in the contributions of individual diseases.

        Speaker: Yue Huang (International Agency for Research on Cancer)
      • 7
        Headache and tinnitus in the international Cohort Study of Mobile Phone Use and Health (COSMOS), France

        Background: Evidence regarding associations between mobile phone use and headache or tinnitus remains inconclusive, despite the concerns of long-term health effects of RF-EMF exposure from mobile phone. We investigated the association of headache and tinnitus in the French component of the prospective Cohort Study of Mobile Phone Use and Health (COSMOS).
        Methods: Using the data from 11,973 COSMOS-France participants responding to both baseline (2017–2019) and follow-up (2025) questionnaires, we assessed detailed mobile phone use including regular use, call frequency and duration, text messaging, and smartphone activities through self-reporting. Odds ratios (OR) and corresponding confidence interval (95% CI) for the associations of mobile use at bassline with incident weekly headaches, severe weekly headaches, self-reported tinnitus, and clinically diagnosed tinnitus were calculated using multivariable logistic regression, adjusting for sociodemographic and lifestyle factors. We also investigated sex-specific differences of these associations.
        Results: Regular mobile phone use was not associated with incident weekly headaches (OR: 1.02, 95% CI: 0.64–1.61) but showed an increased ORs for severe weekly headaches (OR: 1.29, 95% CI: 0.57-2.95). We did not observe an association of regular mobile use with incident self-reported tinnitus (OR 0.96, 95% CI: 0.70-1.30) but observed an indicative association with incident clinical tinnitus (OR:1.46, 95 % CI: 0.88-2.43). Frequency and duration of calls, smart phone use and internet surfing displayed some elevated ORs in relation to severe weekly headaches and clinical tinnitus, with confidence intervals generally including unity. Sex-stratified analyses suggested higher incident headaches among women than men, without statistically significant interactions. Several mobile phone use variables were found to be associated with increased odds of clinical tinnitus among men, with evidence of sex interaction for selected exposure measures.
        Conclusions: We found sex-specific suggestive associations of mobile phone use and headache among female and mobile use and clinical tinnitus among men. The observed differences warrant further investigation in larger prospective studies with longer follow-up, improved exposure assessment, and consideration of additional confounding factors.

        Speaker: Nirmala Prajapati (IARC)
      • 8
        International incidence of lip cancer: a comparative analysis with tobacco- and ultraviolet radiation-related cancers

        Background: Lip cancer is rare and often grouped with oral cancer in epidemiological analyses due to its low caseload and shared risk factors, such as tobacco. However, ultraviolet (UV) radiation is also associated with cancer of the outer lip. To explore geographic variations and infer potential etiological drivers, this ecological study compared age-standardized incidence rates (ASIRs) and trends for lip cancer with lung and mouth cancers (tobacco-related), and melanoma (UV-related).
        Methodology: ASIRs and incidence trends were assessed using data from the Cancer Incidence in Five Continents (CI5) database (2013-2017), and CI5plus (1953-2017). Comparisons were performed for 20 countries with highest lip cancer ASIR.
        Results: In 2013–2017, Portugal and Australia had the highest ASIRs among males (4.8 and 3.7 per 100,000, respectively) and females (0.8 and 1.1). Lip cancer incidence correlated positively with melanoma in males (Spearman’s ρ=0.33, p=0.022) and females (ρ =0.31, p=0.048). External lip was the predominant anatomical subsite in both sexes. Among males, lip cancer ASIRs decreased in most countries, similar to changes observed for tobacco-related cancers in nine countries, while melanoma ASIRs increased. Among females, lip cancer ASIRs were stable or decreased, while ASIRs of mouth cancer, lung cancer, and melanoma generally increased.
        Conclusion: In males, lip cancer patterns in some countries suggested a combined contribution of tobacco and UV radiation, while in others they mirrored tobacco-related cancers; in females, the main drivers remain unclear. Identifying risk factor profiles relevant to different populations could inform country-specific lip cancer prevention strategies and guide future epidemiological research.

        Speaker: Lady Paola Aristizabal Arboleda (IARC)
      • 9
        Preventable burden of infection-related cancers among newly arrived migrants in the European Union

        Background: Migration patterns are diversifying globally, and in 2024 over 5 million migrants arrived in the European Union (EU). Newly arrived migrants (defined here as individuals relocating into countries in the EU between 2020-2024) are identified by European Centre for Disease Prevention and Control (ECDC) as a priority population for entry health assessments. These assessments represent a key opportunity to prevent infection-related cancers. But currently, ECDC guidance only includes prevention services for one of the main cancer-causing infections -- viral hepatatitis (and only for migrants from a small number of countries) -- and excludes the two largest infectious causes: HPV (cervical cancer) and H. pylori (gastric cancer).
        Methods: Using a publicly available competing risk model (ATLAS, from IARC/WHO) and data on migrant population, cancer incidence, and preventive interventions, we estimated the lifetime expected burden of hepatocellular carcinoma (HCC), cervical cancer (CvC), and gastric cancer (GC) cases among migrants arriving in the EU over the most recent five years, and the proportion that could be preventable through vaccination and screening upon arrival.
        Results: Among newly arrived migrants, we expect 635,000 cancer cases over their lifetime (144,000 HCC, 154,000 CvC, 336,000 GC). Current ECDC-recommended hepatitis screening could prevent 15% of HCC cases among migrants, while adding CvC and GC prevention could prevent 55% and 44% of cases, respectively. Expanding viral hepatitis prevention services to a broader criteria of eligibility based on ASIR could increase the number of HCC cases prevented by 83%.
        Conclusions: Migrants to the EU may bear a large burden of preventable cancer cases without access to simple, appropriate prevention services. Providing these health services at entry could help overcome healthcare access barriers. Expanding eligibility and ensuring care continuity throughout migrants' stay in the host country could further increase impact.

        Speaker: Rachel Wittenauer (IARC)
    • 11:45
      Coffee break RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
    • Career Panel RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
    • 13:00
      Lunch
    • Career Workshop RC 103 - PLENIERE 52 PLACES (Nouveau Centre)

      RC 103 - PLENIERE 52 PLACES

      Nouveau Centre

      52
      Show room on map
      • 10
        Forks in the Road: A Career Development Workshop External

        External

        Facilitated by Dr Errol Norwitz, this online workshop aims to help broaden and reframe perspectives on what a career in global health can look like as a researcher and stakeholder within a changing global health landscape. It also aims to help prepare you for your next interview – be it in academia, industry or a global organisation such as IARC.
        Topics covered include:
        • Knowing your WHY
        • The changing job market
        • Pitching yourself
        • Navigating Career Pivots

        The workshop will also comprise shared discussion and activities in breakout rooms as well as a bit of pre-workshop preparation.

        Register to attend by the 17th of November: https://forms.cloud.microsoft/e/NiuG5y6C0W

        Speakers: Cassandra Mbanje (IARC), Dr Errol Norwitz (Babson College)
  • Wednesday 25 November
    • Welcome to ECSA Day: Day 2 RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
    • Cancer Screening, Early Detection & Health Systems RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
      • 11
        Cost-effectiveness models of lung cancer screening by LDCT in Europe from 2015 to 2026: a systematic review and methodological assessment adapted for France

        INTRODUCTION: Low-dose CT screening (LDCT) reduces lung cancer mortality by detecting tumours at earlier, more treatable stages, but implementing it is costly. Before France's pilot programme, IMPULSION, is extended nationwide, its efficiency needs to be established. We conducted a systematic review of European cost-effectiveness models of lung cancer screening, with methodological assessments, to identify elements relevant to a future French model.
        METHODS: We searched PubMed, Embase and Cochrane (2015–2026) for European decision-analytic models evaluating the cost-effectiveness of LDCT screening. Study selection, quality assessment and data extraction, including incremental cost-effectiveness ratio (ICER) in euros per quality-adjusted life years (QALY), were performed independently by two reviewers.
        RESULTS: Twenty-one studies from 14 European countries were included. ICER varied between 2,345-50,000€/QALY gained, median 11,487€, but studies rarely accounted for the same costs. Scan, diagnosis and treatment costs were included everytime, but only 66% of studies included recruitment costs (invitations, phone calls) and 24% included organisational costs (communication, infrastructure), despite their influence on real-world feasibility. Participation rates also varied widely across models (25–100%) but were rarely tested in sensitivity analyses. Costs of innovative treatment (immunotherapies/targeted therapies) were included in only 67% of studies whereas most are less than 10 years old.
        CONCLUSION: These findings confirm that LDCT screening is generally cost-effective with ICERs < 50,000€/QALY, a threshold commonly considered acceptable, in populations comparable to IMPULSION's. They also highlight two under-explored determinants for a future French model: organisational costs and real-world participation, both critical to assessing the feasibility of nationwide screening in France.

        Speaker: Lucie Simon (Université Lyon 1, Inserm U1290 Research on Healthcare Performance (RESHAPE), Lyon, France)
      • 12
        SisConeCta-SP: An Integrated Information System to Support Organized Breast and Cervical Cancer Screening in São Paulo, Brazil

        Background: Organized cancer screening requires integrated information to identify the target population and ensure timely screening and diagnostic follow-up. In São Paulo, screening data are distributed across multiple information systems, limiting individual-level monitoring. This study describes SisConeCta-SP, an integrated information system developed to support organized breast and cervical cancer screening.

        Methods: SisConeCta-SP integrates data from SISCOLO, SISMAMA, SISCAN, e-SUS, and municipal databases, linking examinations to individual women. Dashboards and lists identify women eligible for screening, overdue for screening, or requiring diagnostic follow-up. The system allows health professionals to record relevant events and incorporate examination results from the private sector. An invitation functionality prioritizes women for active outreach according to defined criteria, while record deduplication allows municipalities to identify and merge records not automatically linked. Performance indicators will monitor program impact, including screening coverage, time from examination to result release, time from abnormal result to diagnostic confirmation, and adherence to diagnostic follow-up after abnormal mammography.

        Results: Primary Health Care professionals are already using the system to identify women overdue for screening and those who have never been screened. Estimated cervical cancer screening coverage was 56.9% among women aged 25–64 years during 2023–2025, while mammography coverage was 42.7% among women aged 50–69 years during 2024–2025. These estimates provide an initial baseline for monitoring screening performance.

        Conclusion: SisConeCta-SP enables integrated, individual-level monitoring of the screening pathway, supporting proactive management, active outreach, data quality improvement, identification of gaps in screening and follow-up, and evaluation of program performance over time.

        Speaker: Dr Alice Barros Câmara (International Agency for Research on Cancer)
      • 13
        Supporting childhood cancer registration through the ChildGICR educational program: Impact evaluation

        Background
        The ChildGICR educational program was created by the IARC and the St. Jude Children’s Research Hospital to build capacity and develop childhood cancer registration where it is lacking. We evaluated the impact of the programme on advances in childhood cancer registration.
        Methods
        A biphasic cross-sectional impact evaluation study was conducted using two questionnaires designed using REDCap. The Masterclass survey 2024 targeted the professionals tutored as the ChildGICR trainers, three years post-training. The End Courses questionnaire 2025 targeted graduates one to three years post-training. Outcome measures included satisfaction with training, content retention and use, knowledge dissemination, contributions to childhood cancer registration, and publications. Responses were analyzed using descriptive statistics, binary logistic regression or ordinal logistic regression, and qualitative assessment of open-ended answers.
        Results
        Twenty (100%) trainers completed the Masterclass survey, and 70 of 124 graduates completed the End Course questionnaire. Trainers and graduates reported remembering 61% and 62% of content, respectively. Trainers (N=15) and graduates (N=46) shared acquired knowledge and skills. Fifteen (75%) trainers and 32 (46%) graduates contributed to childhood cancer registration after training, including six (40%) and 25 (78%) attributing their contribution to ChildGICR training. Fifteen (21%) graduates contributed to publications, including 12 (80%) attributing this output to the program.
        Conclusion
        The ChildGICR educational program demonstrates a positive impact on the development of childhood cancer registration. Strengthening and expanding the program is warranted to build capacity and to assess progress of the WHO Global Initiative for Childhood Cancer.

        Speaker: Tristan Thabuis (IARC)
      • 14
        A modified Delphi-study to develop a consensus-based tool for assessing sustainability of organised cancer screening programmes in Europe

        Background: The benefits of cancer screening are realised only when effective organised cancer screening programmes (OCS) are sustainably implemented. Although several frameworks conceptualise sustainability, no practical assessment tool exists for OCS. EUCanScreen Work Package-4 aims to develop a consensus-based tool for this purpose.
        Methods: A four-stage modified Delphi study is being conducted with a purposive panel of policymakers and screening experts. Candidate statements were derived from existing sustainability frameworks and consensus-based criteria for OCS. In Round 1, panellists rated statements on a 5-point importance scale; in Round 2, revised statements were rated as Essential or Desirable. Ratings were summarised descriptively, and comments were analysed qualitatively to inform revision, merging, deletion and addition of statements. In the ongoing Round 3, panellists will confirm the statements and assess the rating descriptors, followed by an online consensus meeting.
        Results: Seventeen experts from 16 countries participated; 14 completed Round 1 and 16 completed Round 2. Of 94 initial statements, 47 were rated 4 or 5 (5 being highly important) by at least 90% of panellists. Revisions yielded 63 statements for Round 2, of which 31 were rated Essential by at least 75% of panellists. Common comments highlighted that some constructs may not apply to all health systems, some statements describe intentions rather than actual practices, and some expect unrealistic capacities. Further refinement resulted in 54 statements (39 Essential, 15 Desirable), with rating descriptors proposed for Round 3.
        Conclusion: This study will produce the first field-ready tool for assessing the sustainability capacity of OCS.

        Speaker: Miller Gnana Sundari Jeyachandran (IARC)
      • 15
        Age-Specific Effects of Organized Mammography Screening Programs on Breast Cancer Mortality Across Varying Coverage: A Population-Based Comparative Study

        Aim
        Evidence on organized mammography breast cancer screening (BCS) reflects mainly overall effects. We aim to estimate age-specific breast cancer mortality reductions attributable to BCS.
        Methods
        This population-based difference-in-differences study paired countries by similarity and screening initiation. The earlier-initiating country served as the screening country and the later-initiating country as the control. Pairs with significantly different pre-screening mortality trends (p ≤ 0.05) were excluded. Age-specific effects were estimated by comparing mortality changes between corresponding cohorts in each pair. The assumed log-linear coverage–effect relationship was evaluated using mean absolute error (MAE) and mean absolute percentage error (MAPE). Overall population-level effects were obtained by aggregating age-specific reductions using standard population weights.
        Results
        The UK–Ireland and Hungary–Poland pairs were eligible, with the UK and Hungary serving as screening countries. In the UK–Ireland pair (64% coverage), reductions increased with age from 9.6% (95% CI, −0.8% to 18.9%) at ages 55–59 to 38.9% (32.1%–45.0%) at ages 65–69, remaining substantial through age 79. Similar patterns were observed in Hungary–Poland (45% coverage). After rescaling coverage to 45%, modeled reductions from UK-Ireland closely matched observed reductions in Hungary–Poland (MAE, 0.017; MAPE, 6.1%). Modeled overall mortality reductions increased from 15.9% (95% CI, 10.9%–20.5%) at 45% coverage to 21.8% (15.1%–28.0%) at 64% and 31.9% (22.5%–40.1%) at 100%.
        Conclusion
        Breast cancer screening effectiveness depended primarily on coverage and lifetime screening duration. Age-specific estimates may inform assessments of progress toward the WHO Global Breast Cancer Initiative target.

        Speaker: Meiwen Yuan (IARC)
    • 11:00
      Coffee break + group photo RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
    • Cancer Screening, Early Detection & Health Systems: Part 2 RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
      • 16
        Impact of registration practice on incidence of childhood CNS tumours: assessment of population-based cancer registries

        Background:
        Central nervous system (CNS) tumours represent 20% of all childhood cancers, with up to 40% non-malignant (nmCNS). Variations in reporting of nmCNS tumours by population-based cancer registries limit comparability.
        Objective:
        To analyse the impact of registering nmCNS tumours on incidence rates.
        Methods:
        All records of intracranial and intraspinal tumours were extracted from database of the International Incidence of Childhood Cancer, Volume 3 (IICC-3). Incidence rates per million and 95% confidence intervals (CI) were calculated for pooled groups of registries, stratified by registration of nmCNS in children (age 0-14 years) and presented by the Human Development Index (HDI) level. Through a REDCap questionnaire administered to all IICC-3 registries we explored the reasons for excluding nmCNS.
        Results:
        Data from 225 population-based cancer registries were included. In children, the pooled age-standardised incidence rate per million (ASR) of CNS tumours was 23.2 (N=31421, 95% CI: 23.0-23.5) where only malignant CNS tumours were registered, and 29.6 (N=119662, 95%CI: 29.4–29.8) where nmCNS were included. Incidence was lowest in the areas with low HDI and highest in the areas with very high HDI. The major determinants of registration of the nmCNS tumours were administrative requirements, funding and personnel.
        Conclusion/Implications:
        Excluding nmCNS tumours from registration underestimates incidence of CNS tumours. Registration of nmCNS tumours may reflect limitations in diagnostic capacity, difficulty to access medical records or gaps in information system; prevalent in lower HDI settings. These findings, generated through the ChildGICR collaboration, underscore the importance of registration of all CNS tumours in childhood.

        Speaker: Indira Adhikari (IARC)
      • 17
        Should occupational exposure be considered in lung cancer screening eligibility? Results from the Pooled Analysis of Case-Control Studies (SYNERGY)

        Introduction: Current lung cancer screening criteria do not account for additional risk experienced by individuals exposed to occupational carcinogens.
        Method: We used data from the SYNERGY consortium, including 16,786 lung cancer cases and 20,818 controls and assessed exposure to lung carcinogens using a job-exposure matrix. We estimated odds ratios (ORs) of lung cancer for individuals categorized by their smoking and lung carcinogen exposure history.
        Results: USPSTF 2021 criteria classified 16,328 participants (43.4%) as screening eligible. Eligible individuals with 20-25 pack-years of smoking exposure had an OR of 5.20 (95% CI: 4.63-5.84) compared to never smokers. Individuals with 10-20 pack years of smoking exposure who were also exposed to at least one lung carcinogens had a similar odds of lung cancer (OR: 5.05, 95% CI: 4.37-5.85).
        A 6-year risk-threshold of 1.51% based on the PLCOm2012 model classified 32.7% of participants as eligible. Participants with a 6-year risk estimate between 1.51% and 2.0% had an OR of 8.89 (95% CI: 8.04-9.84) compared to never smokers. This OR was similar to that of participants with a PLCOm2012-based 6-year risk estimate between 1.0% and 1.51% who were also exposed to at least one lung carcinogen (OR: 8.51, 95%CI: 7.60-9.52).
        Conclusion: Our results indicate that individuals close to meeting eligibility criteria for LDCT screening who are also exposed to occupational exposures have similar lung cancer risk of as eligible individuals. This study highlights that smoking history should be considered in conjunction with occupational exposures when defining eligibility criteria for lung cancer screening.

        Speaker: Thao Tran (International Agency for Research on Cancer)
      • 18
        Scalability of organised, risk-stratified prostate cancer screening in Europe: application of the Intervention Scalability Assessment Tool across the five PRAISE-U pilot sites

        Background: Following the 2022 European Council recommendation to evaluate organised, risk-stratified prostate cancer (PCa) screening, the PRAISE-U (PRostate cancer Awareness and Initiative for Screening in the European Union) project implemented a risk-stratified screening protocol across five pilot sites. We assessed the conditions required to translate these pilots into sustainable population-based programmes.
        Methods: We conducted a comparative scalability assessment across the five PRAISE-U pilot sites using a modified ten-domain Intervention Scalability Assessment Tool (ISAT), supplemented by TAPIC (Transparency, Accountability, Participation, Integrity, Capacity)-based governance analysis. Evidence was triangulated from the pre-implementation capacity and readiness assessments, facility assessments, multi-level stakeholder consultations and Collaborative User Boards (CUBs), programme key performance indicators, first-round clinical effectiveness outputs, and site-specific economic evaluations. Each domain was scored on a 0-3 readiness scale by consensus by the Scalability team.
        Findings: Across the five pilots, 90,245 men were invited and 15,174 participated (site range 7.1-43%). Compliance with each diagnostic step after Prostate-Specific Antigen (PSA) testing was high, and first-level risk stratification reduced Magnetic Resonance Imaging (MRI) referrals by 48% (range 30-58%). Problem definition was consistently strong, whereas intervention specification was moderate across most sites and lower in Lower Silesia, indicating that the clinical pathway requires further standardisation and context-specific adaptation before wider transfer across health systems. The weakest domains across sites were intervention costs, evidence of effectiveness, implementation infrastructure, and sustainability. Descriptive means of the ten ISAT domains were 2.53 (Galicia), 2.49 (Lithuania), 2.47 (Manresa), 2.03 (Ireland) and 1.99 (Lower Silesia); TAPIC governance composites ranged from 1.6 (Lower Silesia) to 2.1 (Lithuania).
        Interpretation: The core clinical sequence was feasible across contrasting health systems, although wider implementation requires context-specific adaptation, sustainable financing, standardisation, quality assurance, accountable governance, and integration of opportunistic PSA testing.
        Funding This project has received funding from the EU4Health programme under grant agreement 101101217, co-funded by the European Union.
        Keywords: Prostate cancer; Screening; Scalability; ISAT; TAPIC; Implementation research; PRAISE-U

        Speaker: Sathishrajaa Palaniraja (IARC)
      • 19
        Understanding delays to early breast cancer detection in Georgia

        Background: Breast cancer is a leading cause of cancer mortality in Georgia (43 deaths per 100 000 in 2020), yet national screening uptake was only 16% in 2023. Our study examines patient-perceived and system barriers to early detection among self- and screen-detected women.
        Methods: DEDICA Georgia is a cross-sectional study that enrolled women aged ≥18 years with newly diagnosed breast cancer. Pathway intervals were measured from symptom discovery (self-detected) or screening (screen-detected). Within each group, intervals were compared by patient-reported barriers using Kruskal-Wallis tests with Benjamini-Hochberg (FDR) correction.
        Results: Of 201 women, 161 (80.1%) self-detected their cancer; 65% had never received in-person education from a healthcare worker. Self-detected women more often presented at stage III-IV (39.9% vs 11.4%; p=0.001). Their median symptom-to-first-consultation was 52.5 days (IQR 13-138.5), longer among women who waited for symptoms to resolve (133 vs 14 days), reported competing priorities (178 vs 32 days) or health system/access barriers (116.5 vs 32 days; all FDR-adjusted p<0.05). Screen-detected women, mostly entering at specialist level, had a median screening-to-diagnosis of 25 days (IQR 15-42). Diagnosis-to-treatment intervals were similar (25 vs 21 days; p=0.47).
        Conclusion: For self-detected women, delay arose mainly before first consultation and was linked to waiting for symptoms to resolve, competing priorities and access barriers, supporting awareness campaigns and primary healthcare-led education. For screen-detected women, the main interval was between screening and diagnosis, supporting better integration of screening with diagnostic services. Moreover, improving early diagnosis in Georgia would be strengthened through tailored navigation according to each detection pathway.
        Word count: 250

        Speaker: Cassandra Mbanje (IARC)
    • 12:15
      Networking Lunch with Italian Specialties RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
    • Prevention Interventions, Policy & Public Health Impact: Part 1 RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
      • 20
        Global opportunities to avert gastric cancer deaths: mapping the role of primary prevention, early detection, and curative treatment in reducing the cancer burden

        Background: Gastric cancer is one of the most common and deadly cancers globally and most cases are attributable to modifiable risk factors, particularly Helicobacter pylori infections. Survival remains low globally and varies between populations. We estimate the current and future avoidable deaths among people diagnosed with gastric cancer in 2024 to inform targeted gastric cancer prevention.

        Methods: National gastric cancer estimates, population attributable fractions, life tables and 5-year net survival estimates were taken from the literature. We estimated numbers of avoidable deaths within 5 years of diagnosis for patients diagnosed with gastric cancer in 2024, consisting of those deaths avoidable through primary prevention (preventable deaths) and those avoidable through early detection and improved access to treatment (treatable deaths) by country, region, and human development index (HDI) group. Treatable deaths were estimated by eliminating survival differences using 5-year net survival estimates from the literature. The projected avoidable deaths were estimated to 2050 with an age-period-cohort model fitted to historical incidence.

        Findings: Globally, an estimated 429,500 out of 678,200 expected deaths among people at five years after gastric cancer diagnosis were avoidable (63.3%). Out of these, 392,200 deaths were preventable and 37,300 were treatable. Helicobacter pylori infections was the top contributor with 274,700 preventable deaths. Given that no risk factor prevention takes place, early detection and curative treatment improvements could avert a maximum of 194,000 deaths (28.6%). All regions had more than half of deaths avoidable. The proportion of avoidable deaths globally was higher in women than in men (66.6 vs 61.5%) while the age-standardised mortality rate was almost double in men (7.6 vs 3.9 avoidable deaths per 100,000 people). The number of avoidable gastric cancer deaths globally are expected to increase by 31.5% between 2024 and 2050.

        Interpretation: Nearly two-thirds of deaths among people diagnosed with gastric cancer globally could be avoided, mainly through primary prevention targeting Helicobacter pylori. Our study highlights the urgent need for, and potential of, coordinated global interventions especially for primary prevention strategies targeting Helicobacter pylori elimination and tobacco smoking while also scaling up early detection and curative treatment.

        Speaker: Oliver Langselius (IARC)
      • 21
        Development and evaluation of sensory-customised foods for patients with cancer

        Background: Sensory alterations and oral symptoms are common among patients undergoing cancer treatment and can negatively affect food intake, eating enjoyment, and quality of life. This study aimed to develop and evaluate sensory-customised foods designed for patients with cancer.
        Methods: Food concepts were developed and evaluated through a focus group discussion involving patients with cancer. Among the six concepts, cromesquis (croquette) and panna cotta were positively evaluated and selected for further development. Standard and sensory-customised versions were subsequently developed, with flavour modification for the cromesquis and texture modification for the panna cotta. These were then evaluated among healthy participants (n = 68) prior to evaluation among patients with cancer (n = 83).
        Results: Among healthy participants, the modification significantly increased the flavour intensity of cromesquis (p < 0.001) without affecting liking (p = 0.178). Texture modification of panna cotta did not change flavour intensity (p = 0.645) but significantly reduced its liking (p < 0.001). Among patients, similar effects were observed for the flavour-modified cromesquis. However, the texture-modified panna cotta was perceived with less intense flavour (p = 0.024) and received a significantly higher liking score than the reference version (p = 0.007).
        Conclusions: Sensory modifications of foods can be perceived and appreciated differently between patients and healthy subjects. This highlights the importance of involving cancer patients in concept and product development to find optimal products, which can compensate for sensory and oral changes and fit with their hedonic preferences.

        Speaker: Reisya Rizki Riantiningtyas (Institut Lyfe Research and Innovation Centre, 69130 Ecully, France)
      • 22
        Monitoring and enforcing alcohol marketing restrictions in France: a qualitative study

        Background: Alcohol causes an estimated 28,000 new cancer cases annually in France. According to the World Health Organisation, comprehensive alcohol marketing restrictions are a cost-effective policy to reduce alcohol consumption. Although the Loi Évin has restricted alcohol marketing in France since 1993, its public health impact depends in part on adequate monitoring and enforcement. This study explored how the law is monitored and enforced in practice, along with the factors shaping and challenging these activities.

        Methods: We conducted 10 semi-structured interviews (January-September 2026) with stakeholders from non-profit organisations and public institutions. Participants were purposively recruited following stakeholder mapping and snowball sampling. Interviews were transcribed verbatim and analysed using reflexive thematic analysis.

        Results: Stakeholders highlighted a mismatch between the media environment for which the Loi Évin was designed in the early 1990s and today’s digital landscape. Influencers’ limited knowledge of advertising regulations was perceived to facilitate non-compliant commercial partnerships, while industry actors exploited ambiguities in the law. Ephemeral content, high publication volumes and undisclosed partnerships further hindered monitoring. Surveillance and enforcement relied heavily on two non-profit organisations with limited resources, restricting the volume of content monitored. These organisations described litigation as a strategic dilemma: legal proceedings could clarify the law and strengthen its application, but unsuccessful cases risked establishing precedents favourable to the alcohol industry and weakening the regulatory framework.

        Conclusion: Effective regulation in the digital era may require both adapting the existing legal framework to contemporary marketing practices and strengthening monitoring and enforcement capacity to support alcohol-related harm prevention.

        Speaker: Juliette Artignan (IARC)
      • 23
        The European Commission Initiative on Gastric Cancer (EC-GaC): developing H. pylori screen-and-treat guidelines for Europe

        Gastric cancer is the 5th most common cause of cancer-related deaths worldwide; in Europe, 5-year relative survival is under 40%. The European Commission (EC) has launched initiatives to improve the approach to cancer prevention, screening, and care, with the aim of overcoming service inequality across Europe. In 2025, EC selected The International Agency for Research on Cancer to provide the scientific and technical coordination of the EC’s newly launched Initiative on Gastric Cancer (EC-GaC) in collaboration with EC’s Joint Research Centre (JRC).

        Because the majority of gastric cancer cases arise from Helicobacter pylori (Hp) infection, EC-GaC will initially focus on Hp screen-and-treat (S&T) as a primary prevention strategy. The objectives of EC-GaC are to develop evidence-based European guidelines on Hp S&T, and to conduct preparatory work for a future quality assurance scheme for relevant healthcare services. The guidelines will offer evidence-based recommendations and good practice statements on the implementation of S&T as organized, population-based programmes. Developed quality indicators will provide guidance for monitoring and evaluation of the recommendations.

        EC-GaC is a person-centred initiative that will consider the needs of the users throughout all stages of the care pathway. While structure, organisation and delivery of services may vary across countries or regions, this initiative aims to provide sufficient flexibility to enable adaptation to all relevant contexts and health systems beyond Europe.

        Speaker: Taylor James Cromarty (IARC)
    • 14:30
      Coffee break RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
    • Prevention Interventions, Policy & Public Health Impact: Part 2 RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
      • 24
        Chemotherapy initiation among patients with cancer during the COVID-19 pandemic in Brazil: an interrupted time series analysis

        Background: the COVID-19 pandemic disrupted cancer care worldwide, but evidence on its impact on treatment initiation is limited. Understanding how the pandemic affected cancer care is essential to strengthen the national health system during or outside of crises. Objective: to estimate the pandemic’s impact on outpatient chemotherapy initiation in Brazil for all cancers combined and for breast, colorectal and lung cancers. Methods: we assessed outpatient chemotherapy authorizations (APAC; 2015-2024), with initiation defined as the first month with chemotherapy after ≥12 months without it. Monthly initiation rates per 100,000 inhabitants were analyzed by interrupted time series with negative binomial regression, seasonal terms, and Newey-West standard errors. Results: we analyzed 35,158,278 APACs from 2.0 million patients (2015-2024) and identified 1.73 million initiations (2016-2024). Patients on chemotherapy remained stable in March 2020 (pandemic onset), and decreased 2.9% in April, still 3.4% above April 2019. In contrast, initiation dropped in March 2020: -10.2% for all cancers (rate ratio [RR] 0.90;95%CI 0.88-0.92), -14.6% for breast (RR 0.85; 95%CI 0.82-0.89), -5.4% for lung (RR 0.95; 95%CI 0.92-0.97) and -4.7% for colorectal cancer (RR 0.95; 95%CI 0.93-0.97; all p<0.001). After the pandemic onset, initiation grew faster than before the pandemic. Fitted rates returned to expected levels by mid-2022 for lung and colorectal and only by late 2024 for breast cancer. Conclusion: during the pandemic, fewer patients started chemotherapy. This may reflect disrupted screening and diagnosis, postponement of treatment by services due to lockdown or by patients fearing infection, or changes in patients' characteristics due to delayed diagnosis.

        Speaker: Lays Silva de Azevedo (IARC)
      • 25
        Tackling alcohol, smoking, physical inactivity and obesity: projected impact of public health policies on cancer across six Nordic countries.

        Background
        Approximately 30% of cancers in Northern Europe are attributable to modifiable risk factors, yet the preventive potential of specific public health policies remains unquantified. We aimed to estimate the number of cancers that could be prevented by implementing evidence-based tobacco, alcohol, obesity and physical activity policies in six Nordic countries.
        Methods
        Using the PREVENT2 modelling tool, which estimates cancer outcomes under alternative risk factor prevalence scenarios, we projected the cumulative number of cancers prevented until 2070 in Denmark, Finland, Iceland, Norway, Sweden and the Faroe Islands. Each policy was modelled as an independent scenario.
        Results
        Tobacco policies showed the greatest preventive potential: across the six countries, a generational tobacco sales ban could prevent approximately 135 000 cancers, raising the minimum legal age for tobacco sales to 21 years 129 000, and Australian-level tobacco taxation 90 000. For alcohol, warning labels (28 000) and minimum unit pricing (17 000) had the largest effects, and for obesity, restricting the marketing of unhealthy foods to children (20 000). Physical activity policies, including value-added tax exemptions on bicycles and sports, and cycling infrastructure, had smaller effects (around 4 500 to 4 700 cancers each, where modelled).
        Conclusions
        Implementing or enhancing evidence-based policies targeting tobacco, alcohol, obesity and physical inactivity could prevent well over 100 000 cancers in the Nordic countries. These findings give policy makers an evidence base to prioritise the interventions with the greatest impact on the cancer burden.

        Speaker: Yann Becker (IARC)
      • 26
        Stakeholder engagement to co-design a school-based delivery strategy for human papillomavirus (HPV) vaccination in Tamil Nadu, India

        Introduction: Cervical cancer is the second most common cancer among women in India, contributing to one-fifth of the world's cervical cancer burden and one-quarter of related deaths. HPV vaccination of adolescent girls is the first pillar of the WHO cervical cancer elimination strategy. Population-level introduction in India has been gradual and operational evidence for school-based delivery at sub-national scale remains limited. Ahead of a pilot in four Tamil Nadu districts, we conducted an implementation study by employing a structured multi-sectoral stakeholder informed co-design approach to prioritise implementation strategies for school-based HPV vaccine introduction and to assess district readiness.
        Methods: Building on formative research and national/global evidence synthesis, candidate strategies were generated at a facilitated one-day deliberative workshop engaging government directorates (health, immunisation, medical education, school education, and social welfare), professional bodies, technical partners and academia. Strategies were prioritised through dot voting and a Feasibility-Impact matrix, organised by implementation domain and mapped post hoc to Expert Recommendations for Implementing Change (ERIC) clusters. District readiness was assessed separately using the WHO HPV Vaccine Introduction Readiness Assessment Tool (2017).
        Results: Stakeholders informed co-designed and prioritised recommendations included multi-channel pre-rollout IEC, school-based delivery for girls aged 9–14, integration into existing school health (RBSK) platforms, joint Health-Education planning, a uniform dosing schedule aligned with national/WHO guidance, structured pre-rollout planning with an adverse-event management protocol, frontline cadre sensitisation, school recognition, inclusion in the routine government programme, and deployment of trusted community workers. Readiness assessment across the four pilot districts confirmed strong political commitment, detailed microplanning, adequate cold-chain capacity, trained workforce and communication at launch.
        Conclusions: A systematic, stakeholder-informed co-design produced a prioritised, context-adapted implementation strategy set and readiness appraisal for school-based HPV vaccination in Tamil Nadu. Co-design surfaced practical, intersectoral strategies incorporating equity considerations, and offers a replicable approach to inform HPV vaccine introduction and scale-up across Indian states and comparable low- and middle- income settings.
        Keywords: HPV vaccine, Cervical cancer, Stakeholder-informed strategies, Prioritisation, School-based vaccination, India, Tamil Nadu.

        Speaker: Sathishrajaa Palaniraja (IARC)
      • 27
        Perspectives of Stakeholders on Clinical Trial Data Sharing: A Scoping Review

        Background: Clinical Trial Data Sharing (CTDS) for secondary use could improve research transparency and reproducibility. Despite journal and regulatory mandates, actual sharing of data remains rare. While 68.6% of trials intend to share data, under 1% make de-identified datasets public upon publication. CTDS is further hindered by privacy concerns, unharmonized data, and inadequate incentives. This study maps stakeholder perspectives to characterize existing governing frameworks and recommend equitable data sharing strategies.
        Methods: Following JBI methodology and PRISMA-ScR guidelines, we systematically searched PubMed, EMBASE, and Web of Science (April 2025), alongside citation tracking (through February 2026). We included English-language articles (2019–2025) addressing CTDS stakeholder perspectives. Screening utilized a Population-Concept-Context framework, followed by inductive content analysis.
        Results: Of 4,615 records identified, 43 met inclusion criteria, predominantly from Europe and the Americas (68%). Patients and researchers were the most studied stakeholders, while funder perspectives were not identified in our search. Seven cross-cutting themes emerged: privacy, altruism, scientific progress, consent, oversight, trust, and infrastructure. Key barriers included data protection concerns, administrative burden, and fear of scooping, whereas altruism and mandates were primary motivators. Regulatory literacy was universally lacking. Broad consent is operationally preferred but ethically contested.
        Discussion: Operationalizing CTDS requires systemic shifts through infrastructure, policy, and cultural reform. We propose eight recommendations: implement data literacy training, modernize broad consent, reform academic incentives, institute independent multi-stakeholder governance, enable community involvement, expand research on underrepresented stakeholders, invest in shared infrastructures, and establish transparent benefit-sharing mechanisms.

        Speaker: Muhammad Riedha (Hospices Civils de Lyon, Public Health Department, Epidemiology and Clinical Research Unit, 69002 Lyon, France)
    • 15:45
      Break RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France
    • Closing and Prizes RC 150 - Auditorium

      RC 150 - Auditorium

      IARC

      25 avenue Tony Garnier, Lyon, France